| Market Capitalization (Millions $) |
37 |
| Shares
Outstanding (Millions) |
52 |
| Employees |
20 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-135 |
| Cash Flow (TTM) (Millions $) |
-5 |
| Capital Exp. (TTM) (Millions $) |
0 |
Alx Oncology Holdings Inc
Alx Oncology Holdings Inc is a clinical-stage biotechnology company that focuses on developing treatments for cancer. The company's approach centres on harnessing the power of the immune system to fight tumours. Alx Oncology is based in Burlingame, California, and is publicly traded on Nasdaq under the symbol "ALXO."
The company's lead product candidate, ALX148, is an immune checkpoint inhibitor. It works by blocking the CD47 protein, which is typically upregulated on cancer cells, thereby preventing them from evading immune system recognition and destruction. Preclinical data suggest that targeting CD47 can enhance the efficacy of other cancer therapies, such as chemotherapy, and improve patient outcomes.
Alx Oncology is pursuing a broad clinical development program for ALX148 across a range of solid and hematologic tumours. The company's ongoing clinical trials include combination studies with standard-of-care treatments, such as doxorubicin and rituximab, as well as investigational agents, such as anti-PD-1 and anti-PD-L1 antibodies. ALX148 has shown promising results in early-stage trials, prompting the company to advance several clinical programs into later stages of development.
In addition to ALX148, Alx Oncology has a pipeline of other CD47-targeting candidates under preclinical evaluation. The company's early research suggests that these compounds may have unique pharmacologic properties and could further improve cancer therapy outcomes.
Alx Oncology's business model centres on partnering with established biopharmaceutical companies to develop and commercialize its drug candidates. The company has license agreements with several major pharma companies, including Genentech, a member of the Roche Group, and Alexion Pharmaceuticals.
Overall, Alx Oncology Holdings Inc is a rapidly growing biotech company offering a promising approach to cancer therapy through its innovative CD47-targeting technology. The company has a strong cash position, a seasoned management team, and a broad network of collaborators, positioning it to become an industry leader in cancer immunotherapy.
Company Address: 323 Allerton Avenue South San Francisco 94080 CA
Company Phone Number: 466-7125 Stock Exchange / Ticker: NASDAQ ALXO
|
4.7%